Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Posted on by Pencis

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012

Yingqiang Du | Myocardial Infarction | Best Researcher Award

Posted on by Pencis

Dr. Yingqiang Du | Myocardial Infarction | Best Researcher Award

Dr. Yingqiang Du, Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University; Suzhou Municipal Hospital; Gusu School, Nanjing Medical University, China

Dr. Yingqiang Du is a renowned cardiology researcher at The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, and Gusu School, Nanjing Medical University, China. His research focuses on myocardial infarction and ischemic heart disease, exploring inflammation, fibrosis, metabolic remodeling, and novel therapeutic strategies. As the first or corresponding author of multiple high-impact publications, he has significantly contributed to cardiovascular medicine. His work bridges basic and clinical research, influencing treatment advancements and patient care. With ongoing projects funded by prestigious grants, Dr. Du continues to drive innovation in cardiology, shaping the future of cardiovascular health research.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

📚 EARLY ACADEMIC PURSUITS:

Dr. Yingqiang Du began his academic journey with a strong foundation in medical sciences, focusing on cardiology and cardiovascular research. His early education provided him with a deep understanding of human physiology, pathology, and the complexities of ischemic heart disease. With a keen interest in myocardial infarction and its underlying mechanisms, he pursued specialized training and research, laying the groundwork for his future contributions to the field.

🏥 PROFESSIONAL ENDEAVORS:

Currently, Dr. Du is affiliated with The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, and Gusu School, Nanjing Medical University. As a researcher and academic professional, he has taken on significant responsibilities in both clinical and experimental cardiology. His work bridges the gap between theoretical research and practical applications, ensuring that scientific findings translate into improved patient care.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Dr. Du’s research primarily centers on myocardial infarction and ischemic heart disease. His studies delve into various aspects, including:

  • The role of inflammation and fibrosis in cardiovascular conditions.
  • The impact of environmental factors, such as micro(nano)plastics, on heart disease.
  • Novel therapeutic approaches involving bioactive compounds like resveratrol and muscone.
  • The involvement of metabolic remodeling and inflammasome activation in aging cells. His extensive work provides crucial insights into the prevention, diagnosis, and treatment of cardiac disorders.

🌟 IMPACT AND INFLUENCE:

Dr. Du’s research has had a profound impact on the field of cardiology. His studies have contributed to a better understanding of the molecular mechanisms of myocardial infarction and fibrosis, paving the way for new treatment modalities. His findings have influenced clinical practices and have been referenced in various medical and scientific discussions worldwide.

📖 ACADEMIC CITES:

As an established researcher, Dr. Du has authored multiple high-impact publications in reputed journals, including:

  • Journal of Hazardous Materials
  • Clinical and Translational Medicine
  • Experimental and Therapeutic Medicine
  • Bioengineered
  • American Journal of Translational Research These publications, where he serves as either the first or corresponding author, reflect his credibility and expertise in the field. His work has been widely cited by peers, demonstrating its relevance and significance.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Du’s contributions to cardiology are paving the way for future breakthroughs in cardiovascular medicine. His research findings are not only enhancing current medical knowledge but also inspiring upcoming researchers to explore novel therapeutic strategies. Moving forward, his work is expected to contribute significantly to:

  • The development of innovative drug treatments for myocardial infarction.
  • The formulation of preventive measures against ischemic heart disease.
  • The exploration of new molecular pathways for better cardiovascular health. His ongoing commitment to research excellence ensures that his legacy will continue to shape the future of cardiology.

🌍CONCLUSION:

Dr. Yingqiang Du is a distinguished researcher whose groundbreaking contributions to cardiology have significantly advanced the understanding of myocardial infarction and ischemic heart disease. His extensive studies on inflammation, fibrosis, and metabolic remodeling have influenced both clinical practices and future research directions. With multiple high-impact publications and ongoing projects, his work continues to shape modern cardiovascular medicine.

TOP NOTABLE PUBLICATION

Title:  Exposure to polyethylene terephthalate micro(nano)plastics exacerbates inflammation and fibrosis after myocardial infarction by reprogramming the gut and lung microbiota and metabolome

Authors: X., Gu, Xin, Z., Zhang, Zhixuan, L., Zhao, Lin, … X., Wang, Xiaoyan, Y., Du, Yingqiang

Journal:  Journal of Hazardous Materials

Year: 2025